In addition, adjuvant IFN therapeutic efficacy on postoperative recurrence differed between patients with HBV-related HCC and patients with HCV-related HCC; therefore, the adjuvant IFN strategy should be used according to the hepatitis background (195). The gene discussed is IFNA1; the disease is hepatocellular carcinoma.